176 related articles for article (PubMed ID: 38105215)
1. TCGAplot: an R package for integrative pan-cancer analysis and visualization of TCGA multi-omics data.
Liao C; Wang X
BMC Bioinformatics; 2023 Dec; 24(1):483. PubMed ID: 38105215
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
[TBL] [Abstract][Full Text] [Related]
5. TCGAnalyzeR: An Online Pan-Cancer Tool for Integrative Visualization of Molecular and Clinical Data of Cancer Patients for Cohort and Associated Gene Discovery.
Zengin T; Masud BA; Önal-Süzek T
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254834
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Multiomics Analysis Identified IQGAP3 as a Potential Prognostic Marker in Pan-Cancer.
Wang G; Zhou X; Li Y; Zhao M; Zou Y; Lu Q; Wu Y
Dis Markers; 2022; 2022():4822964. PubMed ID: 36164370
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Multiomics Analysis Identified Ubiquilin 4 as a Promising Prognostic Biomarker of Immune-Related Therapy in Pan-Cancer.
Li J; Tong Y; Wang Z; Liu Y; Dai X; Zhu Y
J Oncol; 2021; 2021():7404927. PubMed ID: 34539785
[TBL] [Abstract][Full Text] [Related]
8. Multi-omics characterization and validation of MSI-related molecular features across multiple malignancies.
Zheng Y; Huang Y; Bi G; Du Y; Liang J; Zhao M; Chen Z; Zhan C; Xi J; Wang Q
Life Sci; 2021 Apr; 270():119081. PubMed ID: 33516699
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
10. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
Front Immunol; 2022; 13():994828. PubMed ID: 36405728
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
Front Immunol; 2022; 13():998266. PubMed ID: 36248785
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
15. Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancer.
Luo L; Wang Z; Hu T; Feng Z; Zeng Q; Shu X; Wu A; Huang P; Cao Y; Tu Y; Li Z
Biosci Rep; 2023 Jan; 43(1):. PubMed ID: 36545914
[TBL] [Abstract][Full Text] [Related]
16. The Cancer Omics Atlas: an integrative resource for cancer omics annotations.
Sun Q; Li M; Wang X
BMC Med Genomics; 2018 Aug; 11(1):63. PubMed ID: 30089500
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer.
Wang Y; Chen R; Zhang J; Zeng P
PLoS One; 2024; 19(4):e0299949. PubMed ID: 38635758
[TBL] [Abstract][Full Text] [Related]
18. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
[TBL] [Abstract][Full Text] [Related]
19. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
